Bayesian cost-effectiveness analysis for censored data: An application to antiplatelet therapy

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 434-443

  Wu, David Bin Chia ^a   Tsai, Yi Wen ^a   Wen, Yu Wen ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cost effectiveness acceptability curve; Economic evaluation; Incremental cost effectiveness ratio; Incremental net benefit; Markov Chain Monte Carlo methods

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BAYES THEOREM; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD;

AGED; AGED, 80 AND OVER; BAYES THEOREM; BIAS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; TAIWAN;

EID: 84859187014     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.653510     Document Type: Article

References (26)

1. Goeree R, He J, O'Reilly D, et al. Transferability of health technology assessments and economic evaluations: A systematic review of approaches for assessment and application. ClinicoEconomics Outcome Res 2011;3:89-104
2. Doshi JA, Glick HA, Polsky DP. Analyses of cost data in economic evaluation conducted alongside randomized controlled trials. Value Health 2006;9: 334-340
3. Willan AR, Briggs AH. Statistical analysis of cost-effectiveness data. Chichester: John Wiley & Sons, 2006
4. O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;2:150-63
5. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's Theorem. Health Econ 1996;5:297-305
6. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
7. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999;8:257-61
8. Hout BAV, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:309-19
9. Löthgren M, Zethraeus N. Definition, interpretation and calculation of costeffectiveness acceptability curves. Health Econ 2000;9:623-30
10. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000;17:339-49
11. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the costeffectiveness plane. Health Econ 1998;7:723-40
12. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ 2001;10:303-15
13. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Ann Rev Public Health 2002;23:377-401
14. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461-75
15. Vá zquez-Polo FJ, Herná ndez MAN, Ló pez-Valcá rcel BG. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. Health Econ 2005;14:545-57
16. Vá zquez-Polo FJ, Negrý́n M, Badý́a X, et al. Bayesian regression models for cost-effectiveness analysis. Eur J Health Econ 2005;50: 45-52
17. Blackhouse G, Briggs AH, O'Brien BJ. A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored. Med Decis Making 2002;22:173-7
18. Heitjan DF, Kim CY, Li H. Bayesian estimation of cost-effectiveness from censored data. Stat Med 2004;23:1297-309
19. Fenwick E, Marshall DA, Blackhouse G, et al. Assessing the impact of censoring of costs and effects on health-care decision-making: An example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (Affirm) Study. Value Health 2008;11:365-75
20. Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34
21. Raikou M, McGuire A. Estimating medical care costs under conditions of censoring. J Health Econ 2004;23:443-70
22. Gilks W, Richardson S, Spiegelhalter D. Markov Chian Monte Carlo in Practice. Boca Raton, FL: Chapman & Hall/CRC, 1996
23. Gelman A, Carlin J, Stern H, et al. Bayesian data analysis, 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 2004
24. Genz A. Numerical computation of multivariate normal probabilities. J Comput Graph Statis 1992;1:141-50
25. Geweke J. Evaluating the accuracy of sampling-based approaches to calculating posterior moments. In: Bernado JM, Berger JO, Dawid AP, Smith AFM, eds. Bayesian statistics. Oxford: Clarendon Press, 1992
26. Lumley T, Diehr P, Emerson S, et al. The importance of the normality assumption in large public health data sets. Ann Rev Public Health 2002;23:151-69